Table 2. Incidence of late relapse and death.

	Cumulative incidence of late relapse (up to 5 years post HCT) according to diagnosis among patients who were disease free at one year after HCT
	AML	ALL	CML	MDS	Total
No relapse	2170 (85.4%)	1472 (81.87%)	2176 (87.11%)	582 (89.26%)	6400 (85%)
Relapse	371 (14.6%)	326 (18.13%)	322 (12.89%)	70 (10.74%)	1089 (15%)
Total	2541	1798	2498	652	7489

Cumulative incidence of late relapse according to diagnosis among patients who were disease free and had no cGVHD at one year after HCT
Time after HCT	Probability (95% CI) at different time points after HCT
	AML n=1424	ALL n=1056	CML n=1154	MDS n=302
2 years	9 (7-10)	12 (10-14)	8 (6-10)	5 (3-8)
3 years	11 (10-13)	15 (13-18)	12 (11-15)	8 (5-12)
5 years	15 (13-17)	18 (16-21)	17 (14-19)	10 (7-14)

Cumulative incidence of late relapse according to diagnosis among patients who were disease free and had cGVHD at one year after HCT
Time after HCT	Probability (95% CI) at different time points after HCT
	AML n=1117	ALL n=742	CML n=1344	MDS n=350
2 years	7 (6-9)	13 (11-15)	4 (3-5)	5 (3-8)
3 years	11 (9-13)	15 (13-18)	6 (5-8)	7 (5-11)
5 years	13 (11-15)	18 (16-21)	8 (6-9)	10 (7-13)

	Cumulative incidence of death (up to 5 years post HCT) according to diagnosis among patients who were disease free at one year after HCT
	AML	ALL	CML	MDS	Total
Alive	1922 (75.6%)	1354 (75.31%)	2018 (80.78%)	474 (72.7%)	5768 (77%)
Dead	619 (24.3%)	444 (24.6%)	480 (19.2%)	178 (27.3%)	1721 (23%)
Total	2541	1798	2498	652	7489